CIBC Private Wealth senior healthcare analysts provide deeper insight into the most notable themes within healthcare innovation.
COVID-19 has upended just about everything, and we’re still working through it—how we work, shop, socialize, learn, get healthcare, worship, and care for others. It has laid bare both strengths and weakness in our institutions, processes and systems. The pandemic has altered life for every age group in almost every way. The coronavirus, after all, is not interested in career dreams, childcare situations or travel plans; it is only interested in host cells. Key innovations that emerged during this pandemic will outlive it. Others are yet to reveal themselves but will surely be part of the legacy of COVID-19. CIBC is committed to bringing to you the perspective and insight of top thinkers in various fields on what the legacy of COVID-19 could be. In previous installments, we presented views on biotech and vaccines and on work and careers during the time of COVID-19 (available on our website). In this installment, we discuss artificial intelligence in healthcare with the founder and CEO of an investment management firm that invests in leading-edge health and life sciences companies that are disrupting the healthcare ecosystem. In the future, we’ll present interviews with experts in healthcare management, education, and public health law.
Daniel Lubin received a Bachelor of Science in foreign service from the Georgetown University School of Foreign Service, and a Master of Business Administration with honors from Harvard Business School.
